Tiotropium (as bromide monohydrate) 18mcg/cap; dry pwd in caps for oral inhalation; with inhaler device. Spiriva Handihaler consists of Spiriva capsules and the Handihaler device. Spiriva capsules ...
BARCELONA, Spain — The risk for mortality in chronic obstructive pulmonary disease (COPD) patients being treated with tiotropium is the same whether the drug is delivered by the Respimat Soft Mist ...
Current data do not support increased risks for stroke, heart attack, or death The U.S. Food and Drug Administration today announced that data from a recent review of the Spiriva HandiHaler, a ...
Long-term, Head-to-Head Study Showed SPIRIVA HandiHaler (tiotropium bromide inhalation powder) Significantly Prolonged Time to First Moderate or Severe COPD Exacerbation versus Salmeterol HFA-MDI The ...
Please provide your email address to receive an email when new articles are posted on . Daily tiotropium via the HandiHaler device improved lung function but did not reduce frequency of exacerbations ...
Lannett has entered into an exclusive U.S. commercialization agreement for generic Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals. The 10-year term of the ...
Committee Voted Based on Clinical Data from Eight Efficacy Trials RIDGEFIELD, Conn., Aug. 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and ...
LONDON (Reuters) - A major study on the safety of a mist inhaler used to treat chronic lung disease has found it does not increase the risk of patients dying early, in contrast to an earlier analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results